Data completeness
2/8 — Basic
AMIKIN (amikacin sulfate) by Bristol Myers Squibb is mechanism of action amikacin, an aminoglycoside, binds to the prokaryotic ribosome, inhibiting protein synthesis in susceptible bacteria.
Drug data last refreshed 40m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMIKIN (amikacin sulfate) is an aminoglycoside antibiotic administered by injection that binds to bacterial ribosomes to inhibit protein synthesis. It is bactericidal against a broad spectrum of Gram-positive and Gram-negative bacteria. This is a longstanding antibiotic with established clinical utility in serious infections.
Pre-Launch
Pre-launch phase with minimal commercial infrastructure suggests small, early-stage team building focused on market entry strategy and infrastructure development.
Mechanism of Action
Mechanism of Action Amikacin, an aminoglycoside, binds to the prokaryotic ribosome, inhibiting protein synthesis in susceptible bacteria. It is bactericidal in vitro against Gram-positive and Gram-negative bacteria.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Bristol Myers Squibb is hiring 1 role related to this product
Worked on AMIKIN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.